NRC Form 374
(3-83)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment 46

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

CORRECTED COPY

Licensee	
1. Winchester Medical Center	In accordance with application dated May 2, 1983 and attachments thereto
2. South Stewart Street Winchester, Virginia 22601	3. License number 45-01589-01 is amended in its entirety to read as follows:
	4. Expiration date August 31, 1988
	5. Docket or Reference No. 030-11995

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 50	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem, 6.B
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any sealed source listed in Group IV of Schedule A Section 35.100 of 10 CFR 35	C. 2 curies total for all sources authorized in Subitem, 6.C
D. Iodine 131	D. Iodide	D. 500 millicuries
E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	E. Any	E. 3 millicuries of each byproduct material authorized in Subitem 6.E
F. Uranium	F. Plated Metal	F. 137 Kilograms

ML 20

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 45-01589-01

Docket or Reference number 030-11995

CORRECTED COPY

Amendment No. 46

continued

6. Byproduct, source and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any time under this license
G. Xenon 133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigation Exemption for New Drug" (IND) that has been accepted by FDA	G. 300 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II Schedule A, Section 35.100 Title 10, Code of Federal Regulations.

B. Preparation and used of radiopharmaceuticals for any diagnostic procedure listed in III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

E. In vitro studies.

F. For use as shielding in a linear accelerator.

G. Blood flow and pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities at South Stewart Street, Winchester, Virginia.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulation, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 45-01589-01

Docket or Reference number: 030-11995

CORRECTED COPY

Amendment No. 46

(cont'd) CONDITIONS

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of the following individual(s) for the materials and uses indicated:

Gerald A. Gildersleeve, M.D.	Group VI
George J. Murphy, M.D.	Groups I, II and III In vitro studies Iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction Xenon-133
Partick O'Connel, M.D.	Groups I, II and III In vitro studies Iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction Xenon-133
Don H. Richardson, M.D.	Groups I, II and III In vitro studies Xenon-133
Norman J. Smith, M.D.	Group VI
Lilburn T. Talley, M.D.	Group VI
Margaret Toxopeus, M.D.	Groups I, II, III and VI In vitro studies Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma Xenon-133

13. Licensed material shall be used in accordance with the provision of Section 35.14(b)(c)(3) and (f) of Title 10 Code of Federal Regulations.

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of the license, provided the visiting physician:

A. Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission licensee.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 45-01589-01

Docket or Reference number: 030-11995

CORRECTED COPY

Amendment No. 46

(cont'd) CONDITIONS

14. The licensee shall maintain for inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated January 6, 1978, April 25, 1980 and July 11, 1980; and letters dated May 26, 1978, March 17, 1980, September 15, 1980, September 22, 1980 and May 2, 1983, and attachments thereto; and ALARA program dated January 9, 1981. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 24 1985

By EARL G. WRIGHT
Earl G. Wright
Region II, Nuclear Materials
Safety Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323